Zevalin
Total Payments
$316,648
Transactions
1,734
Doctors
848
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $9,421 | 190 | 150 |
| 2019 | $61,380 | 267 | 175 |
| 2018 | $150,009 | 697 | 397 |
| 2017 | $95,839 | 580 | 326 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $121,500 | 3 | 38.4% |
| Honoraria | $74,650 | 27 | 23.6% |
| Travel and Lodging | $38,000 | 125 | 12.0% |
| Food and Beverage | $37,533 | 1,551 | 11.9% |
| Consulting Fee | $32,400 | 15 | 10.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,500 | 3 | 2.4% |
| Education | $5,065 | 10 | 1.6% |
Payments by Type
General
$195,148
1,731 transactions
Research
$121,500
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| IIS-ZEV-001 | Spectrum Pharmaceuticals Inc. | $85,500 | 0 |
| Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20 Non-Hodgkin's Lymphoma | Spectrum Pharmaceuticals Inc. | $30,000 | 0 |
| The Use of Zevalin to Enhance the Efficacy of Non-myeloablative Allogeneic Transplantation in Patients with RelapsedRefractory CD20 NHL | Aurobindo Pharma USA, Inc. | $6,000 | 0 |
Top Doctors Receiving Payments for Zevalin
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Davis, CA | $126,550 | 10 |
| , M.D | Hematology | Fort Myers, FL | $18,110 | 28 |
| , M.D | Hematology | Danville, PA | $12,828 | 23 |
| , MD | Hematology & Oncology | Jacksonville, FL | $11,909 | 11 |
| , M.D | Hematology | Rochester, MN | $11,331 | 19 |
| , M.D | Hematology & Oncology | Lebanon, NH | $10,936 | 22 |
| , M.D | Hematology & Oncology | New York, NY | $9,277 | 27 |
| , M.D | Medical Oncology | Fort Myers, FL | $6,122 | 13 |
| , DO, MS | Hematology | Boston, MA | $5,641 | 13 |
| , MD | Hematology | Sioux Falls, SD | $5,174 | 9 |
| , MD PHD | Hematology & Oncology | Salt Lake City, UT | $5,005 | 9 |
| , M.D | Medical Oncology | Durham, NC | $4,764 | 5 |
| , M.D | Hematology & Oncology | Monrovia, CA | $4,733 | 9 |
| , M.D | Medical Oncology | Washington, DC | $4,534 | 6 |
| , M.D | Hematology & Oncology | Atlanta, GA | $4,248 | 11 |
| Samuel Mehr | Diagnostic Radiology | Omaha, NE | $4,091 | 8 |
| , MD | Medical Oncology | Saint Louis, MO | $4,038 | 4 |
| , M.D | Hematology | Houston, TX | $3,681 | 5 |
| , MD | Medical Oncology | Albuquerque, NM | $3,661 | 6 |
| , MD | Hematology & Oncology | Vallejo, CA | $3,533 | 6 |
| , M.D | Hematology | Fort Myers, FL | $3,113 | 11 |
| , MD | Hematology | Fort Myers, FL | $3,059 | 8 |
| , M. D | Medical Oncology | Houston, TX | $3,018 | 8 |
| , MD | Medical Oncology | Nashville, TN | $2,988 | 11 |
| , M.D | Hematology & Oncology | Jacksonville, FL | $2,896 | 8 |
Ad
Manufacturing Companies
- Spectrum Pharmaceuticals Inc. $247,351
- Aurobindo Pharma USA, Inc. $69,297
Product Information
- Type Drug
- Total Payments $316,648
- Total Doctors 848
- Transactions 1,734
About Zevalin
Zevalin is a drug associated with $316,648 in payments to 848 healthcare providers, recorded across 1,734 transactions in the CMS Open Payments database. The primary manufacturer is Spectrum Pharmaceuticals Inc..
Payment data is available from 2017 to 2020. In 2020, $9,421 was paid across 190 transactions to 150 doctors.
The most common payment nature for Zevalin is "Unspecified" ($121,500, 38.4% of total).
Zevalin is associated with 3 research studies, including "IIS-ZEV-001" ($85,500).